Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Input metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough Corporation).
Reporting Period: Fiscal year ended December 31, 2000.
Business Overview: A global pharmaceutical holding company engaged in the discovery, development, manufacturing, and marketing of prescription pharmaceuticals, animal health products, and over-the-counter (OTC) consumer health products. Key therapeutic areas include allergy/respiratory, anti-infective/anticancer, cardiovascular, and dermatologicals.
Key Financial Metrics
Revenue: Consolidated Net Sales were $9,815 million for 2000, an 8% increase from $9,116 million in 1999.
- Worldwide Pharmaceuticals: $8,346 million (8% increase).
- Animal Health: $720 million (7% increase).
- Consumer Products (Foot Care, OTC, Sun Care): $749 million combined.
Research and Development (R&D): Expenditures totaled $1,333 million in 2000, representing approximately 14% of consolidated net sales (up from 13% in 1999).
Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text incorporates the Consolidated Statements of Income, Cash Flows, and Balance Sheets by reference to the 2000 Annual Report to Shareholders. Specific values for net income, operating cash flow, gross margins, total debt, and liquidity ratios are not explicitly stated in the provided text.
Material Changes Versus Prior Period
- Product Growth: Significant sales growth was driven by Nasonex (60% increase), Intron A/Rebetron (21% increase), and Temodar (from $36 million to $121 million).
- Product Declines: Sales declined for Claritin-D (not listed separately but Claritin grew 13%), Proventil (-21%), Vancil (-29%), and Imdur (-33%).
- Accounting Reclassification: Certain 1999 amounts were reclassified from selling, general, and administrative expenses to net sales to comply with EITF Issue No. 00-14 regarding sales incentives.
- Customer Concentration: 13% of consolidated net sales in 2000 were made to McKesson HBOC Inc., a major distributor.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: Management stated on February 15, 2001, that manufacturing process and control issues identified by the FDA led to reduced sales of certain products in the U.S. marketplace. Consequently, first-quarter and full-year 2001 sales and earnings are expected to be lower than previously anticipated.
Regulatory Risks (FDA): The FDA has cited deficiencies in Good Manufacturing Practices (GMPs) at facilities in New Jersey and Puerto Rico. Resolution of these issues is required prior to the approval of the New Drug Application (NDA) for Clarinex (desloratadine).
Patent Expirations: The loratadine compound patent for Claritin in the U.S. expires in 2002, and the desloratadine patent expires in 2004. These patents are subject to litigation.
Legal Proceedings:
- DES Litigation: Defendant in 235 lawsuits involving ~400 plaintiffs regarding synthetic estrogens; total claims exceed $1.5 billion. Management believes material liability in excess of accrued amounts is remote.
- Antitrust Actions: Defendant in approximately 100 antitrust actions regarding price discrimination and conspiracy. Most state cases settled; federal class action settled for $22 million in 1996.
- Government Investigations: Subject to investigations by the FTC, DOJ, and HHS regarding Average Wholesale Price (AWP) reporting, disease management programs, and Medicaid best price calculations.
- Securities Litigation: Following the February 15, 2001 press release regarding FDA issues, class action lawsuits were filed alleging violations of the Securities Exchange Act.
Investor Verification Checklist
- Verify the specific impact of FDA GMP deficiencies on Q1 and full-year 2001 earnings guidance in the most recent press releases or 8-K filings.
- Review the status of the Clarinex (desloratadine) NDA approval and the timeline for resolving FDA manufacturing issues.
- Monitor the status of patent litigation regarding Claritin and PEG-Intron, specifically the expiration dates and potential generic entry.
- Assess the potential financial exposure from ongoing government investigations into AWP reporting and Medicaid pricing.
- Confirm the consolidated net income and cash flow figures in the full 2000 Annual Report to Shareholders, as they are not detailed in this 10-K text.